'Recurrent' glioblastoma multiforme, when should we reoperate?

被引：107

作者：

Barbagallo, Giuseppe M. V. ^{[1
,2
]}

Jenkinson, Michael D. ^{[1
]}

Brodbelt, Andrew R. ^{[1
]}

机构：

[1] Walton Ctr Neurol & Neurosurg, Dept Neurosurg, Liverpool L9 7LJ, Merseyside, England

[2] Azienda Osped Univ Policlin G Rodolico, Dept Neurosurg, Catania, Italy

来源：

BRITISH JOURNAL OF NEUROSURGERY | 2008年 / 22卷 / 03期

关键词：

chemotherapy; glioblastoma multiforme; radiotherapy; recurrence; reoperation; resection; surgery; glioma;

D O I：

10.1080/02688690802182256

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

The surgical management of recurrent glioblastoma multiforme is controversial. Recent publications suggest that reoperation provides 3-5 months median survival, without significant increases in morbidity or martality. Age (<= 50 years, although older patients may also benefit) and performance status (Karnofsky performance score >= 60-70) are the most important factors. Reresection not only improves symptoms and maintains quality of life, it can delay symptom progression, reduce corticosteroid doses, and also improve response to (and allow intra-operative) chemotherapy and/or radiotherapy. Surgical treatment of recurrent glioblastoma multiforme in selected patients should always be considered.

引用

页码：452 / 455

页数：4

共 37 条

[1] Dynamic susceptibility contrast MRI of gliomas [J].

Aronen, HJ ;

Perkiö, J .

NEUROIMAGING CLINICS OF NORTH AMERICA, 2002, 12 (04) :501-+

[2] Survival and functional status after resection of recurrent glioblastoma multiforme [J].

Barker, FG ;

Chang, SM ;

Gutin, PH ;

Malec, MK ;

McDermott, MW ;

Prados, MD ;

Wilson, CB .

NEUROSURGERY, 1998, 42 (04) :709-720

[3] AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients [J].

Batchelor, Tracy T. ;

Sorensen, A. Gregory ;

di Tomaso, Emmanuelle ;

Zhang, Wei-Ting ;

Duda, Dan G. ;

Cohen, Kenneth S. ;

Kozak, Kevin R. ;

Cahill, Daniel P. ;

Chen, Poe-Jou ;

Zhu, Mingwang ;

Ancukiewicz, Marek ;

Mrugala, Maciej M. ;

Plotkin, Scott ;

Drappatz, Jan ;

Louis, David N. ;

Ivy, Percy ;

Scadden, David T. ;

Benner, Thomas ;

Loeffler, Jay S. ;

Wen, Patrick Y. ;

Jain, Rakesh K. .

CANCER CELL, 2007, 11 (01) :83-95

[4] Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas [J].

Brandsma, Dieto ;

Stalpers, Lukas ;

Taal, Walter ;

Sminia, Peter ;

van den Bent, Martinj .

LANCET ONCOLOGY, 2008, 9 (05) :453-461

[5] PLACEBO-CONTROLLED TRIAL OF SAFETY AND EFFICACY OF INTRAOPERATIVE CONTROLLED DELIVERY BY BIODEGRADABLE POLYMERS OF CHEMOTHERAPY FOR RECURRENT GLIOMAS [J].

BREM, H ;

PIANTADOSI, S ;

BURGER, PC ;

WALKER, M ;

SELKER, R ;

VICK, NA ;

BLACK, K ;

SISTI, M ;

BREM, S ;

MOHR, G ;

MULLER, P ;

MORAWETZ, R ;

SCHOLD, SC .

LANCET, 1995, 345 (8956) :1008-1012

[6]

Brem Steven S, 2005, J Natl Compr Canc Netw, V3, P644

[7] Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors [J].

Chenevert, TL ;

Stegman, LD ;

Taylor, JMG ;

Robertson, PL ;

Greenberg, HS ;

Rehemtulla, A ;

Ross, BD .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2000, 92 (24) :2029-2036

[8]

DEVITA VT, 1983, CANCER, V51, P1209, DOI 10.1002/1097-0142(19830401)51:7<1209::AID-CNCR2820510707>3.0.CO

[9]

2-J

[10] Management of glioblastoma multiforme with special reference to recurrence [J].

Durmaz, R ;

Erken, S ;

Arslantas, A ;

Atasoy, MA ;

Bal, C ;

Tel, E .

CLINICAL NEUROLOGY AND NEUROSURGERY, 1997, 99 (02) :117-123

← 1 2 3 4 →